Medical University of Vienna

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board

Retrieved on: 
Monday, April 8, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Faculty, Medical University of Vienna, Part, Patient, Queen's University, Optometry, Queen's University Belfast, CAB, MD, Royal Victoria Hospital, Laborie (company), Medical school, Therapy, Retina, Safety, AMD, Geographic atrophy, Pharmaceutical industry

Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • The Company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.
  • “We are excited that results from Part 1 of the US Phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, M.D., Aviceda’s Co-founder and CEO.
  • “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”

REVEAL GENOMICS® HER2DX® Genomic Test to Undergo First Prospective Trial as Part of the DEFINITIVE Project, Funded by the European Commission

Retrieved on: 
Wednesday, February 28, 2024
Other Health, General Health, Professional Services, Oncology, Medical Devices, Technology, Clinical Trials, Biotechnology, Finance, Other Technology, Manufacturing, Health, Breast cancer, Hospital, Health technology assessment, Recurrence, Multimedia, Medical school, Principal, Quality of life, Small and medium-sized enterprises, Risk, University, Communication, Health care, HTA, Organization, SME, Medicine, Patient, Optimism, Survival, Knowledge, Medical University of Vienna, Medical imaging

The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.

Key Points: 
  • The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.
  • As a collaborating partner in this study, REVEAL GENOMICS® is committed to generating robust evidence designed to influence and evolve standard clinical practices.
  • We are immensely grateful to all our partners and the multidisciplinary team participating in this trial.
  • The DEFINITIVE trial seeks to assess the clinical efficacy of HER2DX® by comparing the outcomes of patients who undergo the genomic test with those who do not.

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

Retrieved on: 
Tuesday, January 9, 2024
General Health, Health, Surgery, Organ transplantation, Medical University of Vienna, Patient, Risk, CTS, Medical school, Survival, Freezing, Lung transplantation, ECMO, PGD, Physician, Dentistry

The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.

Key Points: 
  • The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.
  • The Paragonix SherpaPak CTS is a static hypothermic preservation device intended to protect the donor heart during transit, standardizing the internal environment to maintain a recommended thermal range above freezing, unlike traditionally used ice-cold storage.
  • Published in the esteemed Journal of Heart and Lung Transplantation, this study compared the effectiveness of ice-cold storage against the Paragonix SherpaPak CTS, assessing the post-transplant outcomes of recipients who received an extended criteria donor heart.
  • “The study finds the Paragonix SherpaPak Cardiac Transport System provides a clinically effective solution to safely increase donor heart utilization.

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
CNS, Lung, Health, Neck, Prostate, Medical University of Vienna, Breast, Brain, Safety, Food, European Medicines Agency, Paediatric-use marketing authorisation, European Commission, Head, University, Medical imaging, Human, Liver, Spine, GBCA, Google Images, PICTURE, Gadolinium, EMA, Civil service commission, Patient, Marketing authorisation, European, Gadobutrol, Neurology, FDA, Kidney, Pancreas, European Committee for Standardization, CHMP, BBB, Monroe Dunaway Anderson, Committee, Pathology, Gastroenterology, MRI, Central nervous system, MD Anderson Cancer Center, Medical school, Environment, Vaccine, Rare-earth element

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.

Key Points: 
  • Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.
  • MILAN, Dec. 11, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announces that on December 7, 2023 the European Commission (EC) has granted the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union (EU).
  • 1,2
    "The final approval of gadopiclenol by the European Commission marks a significant milestone in the field of diagnostic imaging.
  • This innovation benefits healthcare providers but also, more importantly, patients who undergo MRI scans and those living with chronic conditions.

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
CNS, Lung, Health, Neck, Prostate, Medical University of Vienna, Breast, Brain, Safety, Food, European Medicines Agency, Paediatric-use marketing authorisation, European Commission, Head, University, Medical imaging, Human, Liver, Spine, GBCA, Google Images, PICTURE, Gadolinium, EMA, Civil service commission, Patient, Marketing authorisation, European, Gadobutrol, Neurology, FDA, Kidney, Pancreas, European Committee for Standardization, CHMP, BBB, Monroe Dunaway Anderson, Committee, Pathology, Gastroenterology, MRI, Central nervous system, MD Anderson Cancer Center, Medical school, Environment, Vaccine, Rare-earth element

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.

Key Points: 
  • Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.
  • MILAN, Dec. 11, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announces that on December 7, 2023 the European Commission (EC) has granted the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union (EU).
  • 1,2
    "The final approval of gadopiclenol by the European Commission marks a significant milestone in the field of diagnostic imaging.
  • This innovation benefits healthcare providers but also, more importantly, patients who undergo MRI scans and those living with chronic conditions.

Patient Experience Journal, published in association with The Beryl Institute, Releases Volume 10, Issue 3

Retrieved on: 
Tuesday, November 7, 2023
Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Medical University of Vienna, Oregon Health & Science University, Ariel University, Research, Agility, University of California, San Francisco, University, Implementation research, Medical school, University of Alabama, Northwestern Health Sciences University, University of Michigan, Movement, Nursing, Management

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 3 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • "This issue closes the first decade of Patient Experience Journal's (PXJ) contribution to evidence and innovation, to sharing stories and research, to elevating the conversation and pushing the boundaries of the experience movement."
  • said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • "We have never hesitated to nudge at the status quo or to respond with agility to the challenging moments we have faced.
  • We have welcomed diverse voices as contributors, and we have seen an even more diverse readership."

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia

Retrieved on: 
Tuesday, September 19, 2023
Science, Research, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, BAT, Civil service commission, Polycythemia vera, European Hematology Association, Hydroxycarbamide, Medical school, Multimedia, Ropeginterferon alfa-2b, H, Patient, Titan IIIB, AOP, Annual general meeting, Medical University of Vienna, Paper, ATC, Polycythemia, Leukemia, European Commission, Safety, Disease, Pharmaceutical industry, PV

AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.

Key Points: 
  • AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.
  • The full publication expands on results presented at the Annual Meeting of the European Hematology Association.
  • Results of long-term treatment in the CONTINUATION-PV study provide further evidence of the disease modifying capacity of ropeginterferon alfa-2b in PV.
  • Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

CareDx Advances Global Transplant Patient Care at ESOT Congress 2023

Retrieved on: 
Thursday, September 14, 2023
Biotechnology, Surgery, Hospitals, Health, Clinical Trials, Abstract, DNA, Paris Institute for Advanced Study, Comparison, Nucleic acid thermodynamics, Transplant, Doctor of Philosophy, Necker–Enfants Malades Hospital, Organ transplantation, Teaching hospital, University Hospital of Zürich, Associate, Congress, Plasma, Lung transplantation, Nephrology, Local, MD, Patient, Risk, Medical University of Vienna, UZ Leuven, Harbin Medical University, Paris, European Society for Primary Immunodeficiencies, Caregiver, Dentistry, Medical device, Epidemiology

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
  • CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA.
  • “We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx.
  • CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.